- Mid-Regional pro-Adrenomedullin (MR-
- proADM), C-Reactive Protein (CRP) and Other
- **Biomarkers in the Early Identification of**
- Disease Progression in COVID-19 Patients in
 the Acute NHS Setting.
 - Nathan Moore^{1#}, Rebecca Williams^{1#}, Matilde Mori², Beatrice Bertolusso¹, Gabrielle Vernet¹, Jessica Lynch¹, Peter Philipson³, Thomas Ledgerwood¹, Stephen P. Kidd¹, Claire Thomas¹, Veronica Garcia-Arias¹, Michelle Young⁴, Kordo Saeed^{2,5}, Kirsty Gordon¹, Nicholas Cortes^{1,2,6,7*}
- 11 ¹Hampshire Hospitals NHS Foundation Trust, Basingstoke and North Hampshire Hospital,
- 12 Basingstoke, UK

8

9 10

19 20 21

22

25

28 29 30

31

32

33

34 35

36 37

38 39

40

41

42 43

44 45

46

47 48

- ²University of Southampton, School of Medicine, UK
- ³Newcastle University, School of Mathematics, Statistics & Physics, UK
- ⁴Whittington Hospital, London, UK
- 16 ⁵University Hospital Southampton NHS Foundation Trust, Southampton, UK
- 17 ⁶Gibraltar Health Authority, Gibraltar, UK
- 18 ⁷University of Gibraltar, Gibraltar, UK
 - #Joint first authors
 - *Corresponding author:
- 23 Nick.cortes@hhft.nhs.uk
- 24 01256 473202
- Keywords: MR-proADM, SARS-CoV-2, COVID-19, Mortality, Biomarkers, Emergency Department,
 Disease progression

Background: There is a lack of biomarkers validated for assessing clinical deterioration in COVID-19 patients upon presentation to secondary or tertiary care. This evaluation looked at the potential clinical application of a range of biomarkers, including C-Reactive Protein (CRP) and Procalcitonin (PCT) and Mid-Regional pro-adrenomedullin (MR-proADM), and White Cell Count to support prediction of clinical outcomes.

Methods: Adult patients presenting to Hampshire Hospitals NHS Foundation Trust between April and June 2020 confirmed to have COVID-19 via RT-qPCR were included. Biomarkers were measured in blood samples taken within 24 hours of admission and logistic regression and area under the receiver operating characteristic (AUROC) curves were used to predict disease progression. The endpoints assessed were 30-day all-cause mortality, intubation and ventilation, admission to critical care and non-invasive ventilation (NIV) use.

Findings: A total of 135 adult patients were identified. Elevated levels of MR-proADM were shown to have the greatest ability to predict 30-day mortality adjusting for age, cardiovascular disease, renal disease and neurological disease. A significant association was also noted between raised MR-proADM and CRP concentrations and the requirement for critical care admission and non-invasive ventilation, when controlling for covariates.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Interpretation: The measurement of biomarkers, particularly MR-proADM and CRP in patients with confirmed COVID-19 infection upon admission to secondary care shows significant potential to support clinicians in the early identification of those at increased risk of disease progression and need for higher level care, subsequently enabling prompt escalation in clinical interventions and treatment.

Funding: No funding was required for this article

Introduction

Since initial reports of a cluster of pneumonia cases arising from Wuhan, Hubei and the subsequent identification of the causative *betacoronavirus*, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected over 100 million people globally and directly resulted in the deaths of approximately 2.3 million by January 2021.

The progressive multi-organ failure associated with SARS-CoV-2 mortality is driven in part by significant inflammation and microvascular thrombosis. Presence of SARS-CoV-2 within the endothelium can cause a secondary endotheliitis and an impairment of vascular blood flow, a prothrombotic state and vascular leakage.(1) During endotheliitis there is elevation of biomarkers, such as neutrophil extracellular traps, that can lead to microvascular thrombosis and inflammation.(2)

Adrenomedullin is a peptide that has been shown to have a role in preserving the integrity and stability of the endothelium after severe infection. Furthermore, it has potent vasodilatory properties, as well as having a role in immunomodulation and metabolic regulation. It is upregulated in several pathogenic processes, including sepsis and the progression of septic patients towards multi-organ failure(3-5).

The novel biomarkers mid-regional proadrenomedullin (MR-proADM) has also been shown to be predictive of poor clinical outcomes in patients with sepsis and infections involving the respiratory(6, 7) and urinary(8, 9) systems. Similarly, it has been demonstrated during non-infective processes such as heart failure and kidney injury(10). As a precursor amino acid sequence that splits from proadrenomedullin, MR-proADM is used as a surrogate marker for adrenomedullin. It can be measured via an automated immunofluorescent assay, as levels are directly proportional to adrenomedullin which rapidly breaks down in blood.

The instigation of an appropriate management plan is dependent on an adequate assessment of the infection severity, which is determined by the host pathophysiological response and the virulence of the organism causing infection.

However, infection is a dynamic process with infection severity changing over time within an individual. As infection progresses, patients may transition from low severity to high severity which if not identified, may lead to delayed or inappropriate therapy.

Therefore, biomarkers that could help stratify risk of disease progression are of clinical interest as they may help guide appropriate early management and patient placement within hospital. A recent study by Saeed *et al.* found that the measurement of MR-proADM could effectively predict disease progression; identifying those at increased risk of mortality, those who would need ICU admission and those requiring a longer length of stay in hospital. Furthermore, they identified its potential use in facilitating early discharge from hospital, with no increase in mortality.(11)

The aim of this study was to assess the effectiveness of a number of biomarkers, both established and emerging, in the acute setting as prognostic markers to support clinicians in the early identification of patients with Covid-19 at risk of mortality, ICU admission and ventilation.

Methods

Study Design and Data Collection

In this observational study, we identified adult patients confirmed to have SARS-CoV-2 at a district general hospital, Hampshire Hospitals NHS Foundation Trust, during the first wave of the virus between April and June 2020. SARS-CoV-2 was detected by real-time reverse-transcription PCR (rRT-PCR) using the COVID-19 genesig® Real-Time PCR assay (Primerdesign Ltd, Chandler's Ford, UK). All blood samples analysed were collected as part of routine clinical care on admission to hospital. Measurement of C-reactive protein (CRP) on serum samples was performed on ADVIA 2400 analysers; procalcitonin (PCT) on Centaur XP analysers and full blood count (FBC) and differential white blood cell counts were performed on Ethylenediaminetetraacetic acid (EDTA) samples on Siemens Advia 2120i (all Siemens Healthineers, Tarrytown, New York, USA). Measurement of MR-proADM was performed (within 72hours of collection, in line with manufacturer's guidance) on EDTA blood samples taken on admission using an immunoassay (B.R.A.H.M.S. KRYPTOR™, Thermo Fisher Scientific, Henningsdorf, Germany).

Patients were followed up until discharge, with demographics, comorbidities, admission and discharge dates, non-invasive ventilation (NIV) use, need for intubation and ventilation, admission to ICU and mortality data being anonymously collected.

Statistical Analysis

Time to event analysis was performed with univariate and multivariate Cox proportional hazard models. However, this was only performed for clinical outcomes with a sufficiently high event per variable ratio.(12, 13) Time to event analysis was right-censored at 30 days. The Cox proportional hazard models were checked for proportionality by correlating sets of scaled Schoenfeld residuals with time, to test for independence between residuals and time. Where proportionality was not met stratification was performed as necessary. Hazard ratios and C-index score were calculated with corresponding 95% confidence intervals. Confounding variables for the multivariate analysis were selected based on those that were significant upon univariate logistic regression following Bonferroni correction, with a p-value of <0.005.

Symmetrically distributed variables were reported using the mean (standard deviation), whereas variables exhibiting a skewed distribution were reported using the median [first quartile – third quartile]. The Chi-square test (χ 2) was used to assess differences in categorical variables in the demographics and clinical characteristics between those who did and did not die within 30 days, with the Mann-Whitney U test being used to assess differences in continuous variables and Student's T-test for age.

Data analysis was performed using R version 4.0.1.

Receiver operating characteristic (ROC) curves with area under the curve (AUC) analysis was used to determine predictive value for each clinical endpoint with 95% confidence intervals to establish significance. To investigate if individual biomarkers offer a significant improvement in predicting an adverse outcome over a model incorporating previously identified confounding variables, as outlined above, AUC analyses were compared using a bootstrap method.

Results

Samples from 135 patients in total were analysed with a mean age of 64.6 years and a predominance of males (51.9% male vs 48.1% female). The patient group included 105 who had survived by thirty days post admission and 30 who had died by this timepoint. The characteristics of the patient cohort are described in Table 1.

Median biomarker concentrations in this group showed elevated median CRP 59mg/L (Q1-Q3 range 17-143) and MR-proADM 1.02 nmol/L (Q1-Q3 range 0.71-1.61); median levels within normal clinical ranges for total white blood cell count 7.1×10^9 /L (Q1-Q3 range 5.2-9.65), neutrophils 5.31×10^9 /L (Q1-Q3 range 3.51-7.66) and PCT 0.13ng/mL (Q1-Q3 range 0.07-0.41) but a suppressed median lymphocyte count 0.98×10^9 /L (Q1-Q3 range 0.70-1.36).

Twenty-five of these patients were enrolled into the RECOVERY trial with 9 receiving standard care, 6 received hydroxychloroquine, 6 received Lopinavir-Ritonavir and 3 received Azithromycin, all of which were deemed to have no clinical benefit.(14-16) One patient received dexamethasone as part of the RECOVERY trial. Otherwise none of the patients received other immunomodulation, including IL-6 inhibitors (tocilizumab or sarilumab), IL-1 inhibitors (such as anankinra) or convalescent plasma. Multivariate Cox regression adjusted for age, cardiovascular disease, renal disease and neurological disease. Proportionality was checked for all Cox regression models and stratification performed as necessary.

MR-proADM

For this novel biomarker Saeed et al (11) have previously derived and proposed, in a non-COVID-19 acute patient population, a cut-off of 1.54 nmol/L as a predictor of elevated mortality, higher rate of ICU admission and longer length of stay. Applying this cut-off to our COVID-19 patient population shows significantly (p = 1.59×10^{-5}) lower mortality rate of 11.11% (N=11) in the patients with MR-proADM values < 1.54 nmol/L (N=99 (73.33%)) compared to a higher mortality rate of 52.78% (N=19) in patients (N=36, (26.67%)) with MR-proADM values equal to or exceeding a cut-off of 1.54 nmol/L. None of the patients who died (N=30) had a MR-proADM value below the pre-defined threshold of < 0.88 nmol/L (p = 1.61×10^{-9}), previously proposed in a non-COVID-19 population by Saeed et al (11) as a potential cut-off for identifying patients at very low risk for deterioration and no mortality. Of interest, fifty-two (38.52%) patients with MR-proADM values of <0.88 nmol/L had a median inpatient stay of 4 days (interquartile range [IQR] 0.75 - 9 days), representing a significantly shorter length of stay than those with an MR-proADM of >0.88 nmol/L whose median stay was 12 days (IQR 5 - 22.5 days), p <0.00001.

30 Day Mortality

Table 1 compares the patient demographics and clinical characteristics between survivors and non-survivors. Of note CRP, PCT and MR-proADM were all significantly raised amongst those that did not survive at day 30.

Univariate Cox regression analysis found MR-proADM to have the greatest ability to predict 30 day mortality (Wald 20.3, HR 1.5455 [1.279-1.868]), with CRP also proving effective at predicting 30 day mortality (Wald 4.02, HR 1.0034 [1.000-1.007]) as shown in Table 2.

Although PCT was significant for univariate Cox regression analysis (Wald 11.54, HR 1.0898 [1.037-1.145]), the assumption of proportional hazards was not supported for PCT. Rather than attempting to estimate a time-dependent coefficient in order to include covariates with time-varying coefficients multivariate analysis was not performed. Both MR-proADM (Wald 23.735, HR 1.809[1.454-2.407]) and CRP (Wald 12.166, HR 1.0069[1.003-1.011]) remained significant for predicting 30 day mortality following adjustment for age, cardiovascular disease, renal disease and

neurological disease (Table 3). Similarly, lymphocyte count was significant in predicting 30 day mortality after adjusting for co-variates (Wald 6.6564, HR 1.1213[1.028-1.223]).

MR-proADM offered a significant improvement in predicting 30 day mortality over a model combining age, renal disease, cardiovascular disease and neurological disease with an AUC of 0.874 (p=0.01727), whereas CRP did not offer an improvement (p=0.1464).

Intubation and Ventilation

Elevated MR-proADM (Wald 12.37, HR 1.6015[1.232-2.082]) and CRP (Wald 16.57, HR 1.0069 [1.004-1.010]) were both associated with an increase in the need for intubation and ventilation when performing univariate cox regression. No firm conclusions are offered here from a multivariate analysis for prediction of need for intubation and ventilation due to the lower number of events per predictor variable, though the results are suggestive for both MR-proADM and CRP having efficacy in predicting the need for intubation.

Admission to Critical Care

On univariate analysis only CRP demonstrated a significant association with a requirement for admission to critical care (Wald 15.83, HR [1.0055-1.008]), which was maintained once controlled for covariates, however proportionality was affected by renal disease (Chisq 4.2243, p=0.04), which was therefore taken out by stratification (Wald 22.062, HR 1.0078[1.005-1.011]). Although insignificant on univariate analysis MR-proADM (Wald 3.2, HR 1.257[0.978-1.615]) did exhibit a significant association with a requirement for critical care once covariates were controlled for (Wald 10.151, HR 1.5451 [1.182-2.019]).

Only CRP provided an improvement over the previously described combined model with an AUC of 0.8026 (p=0.012).

Non-Invasive Ventilation

Once again elevated CRP (Wald 15.53, HR 1.0061[1.003-1.009]) and MR-proADM (Wald 11.62, HR 1.4992[1.188-1.892]) were associated with requirement for NIV following univariate analysis, with both CRP (Wald 18.293 HR 1.0081[1.004-1.012]) and MR-proADM (Wald 30.393, HR 2.5230[1.816-3.506]) both retaining significance on multivariate analysis. Lymphocyte count was not a constant hazard and so further analysis was omitted rather than estimating a time-dependent coefficient.

Both CRP and MR-proADM offered an improvement over the combined model with AUCs of 0.8544 (p=0.000375) and 0.8139 (p=0.001052) respectively.

Table 1. Characteristics with regards to 30-day mortality

242

243244

245

246247

Patient characteristics	Total patient cohort (N=135)	Survivors (N=105)	Non-Survivors (<i>N</i> =30)	p-value
Demographics				
Age (years) (mean, SD)	64.6 (19.5)	60.0 (18.9)	80.7 (11.6)	1.22x10^- 11
Male gender (N, %)	70 (51.9%)	56 (53.3%)	14 (46.7%)	0.6547
Disease progression and mortality				
Non-Invasive Ventilation (N, %)	23 (17.04%)	14 (13.3%)	9 (30.0%)	0.0511
Intensive care unit admission (N, %)	31 (22.96%)	25 (23.8%)	6 (20.0%)	0.7010
Invasive Ventilation (N, %)	16 (11.85%)	12 (11.4%)	4 (13.3%)	0.6366
30-day mortality (N, %)	30 (22.22%)			
Hospital length of stay (days)(median, Q1-Q3)	8 [3 - 17]	8 [2 – 17]	11.5 [5.25 – 15.75]	0.0722
Comorbidities				
Cardiovascular disease (N, %)	75 (55.6%)	52 (49.5%)	23 (76.7%)	0.0786
Respiratory disease (N, %)	35 (25.9%)	30 (28.6%)	5 (16.7%)	0.2587
Haematological disease (N, %)	5 (3.7%)	5 (4.8%)	0 (0.0%)	0.2320
Immunodeficiency (N, %)	5 (3.7%)	5 (4.8%)	0 (0.0%)	0.2320
Diabetes (N, %)	32 (23.7%)	26 (24.8%)	6 (20.0%)	0.6366
Renal Disease (N, %)	23 (17.0%)	13 (12.4%)	10 (33.3%)	0.0142
Liver Disease (N, %)	9 (6.7%)	8 (7.6%)	1 (3.3%)	0.4227
Malignancy (N, %)	20 (14.8%)	14 (13.3%)	6 (20.0%)	0.4028
Central Nervous System Disease (N, %)	27 (20.0%)	16 (15.2%)	11 (36.7%)	0.0206
Biomarker concentrations				
CRP¹ (mg/L) (median, Q1-Q3)	59 [17 - 143]	52 [13 - 143]	102 [43 – 148.75]	0.0301
White Cell Count (109/L) (median, Q1-Q3)	7.1 [5.2 – 9.65]	7.1 [5.5 – 9.7]	7.0 [4.425 – 8.675]	0.1469
Neutrophil Count (10 ⁹ /L) (median, Q1-Q3)	5.31 [3.51 – 7.66]	5.33 [3.72 – 8.0]	5.23 [3.235 – 6.8475]	0.2005
Lymphocyte Count (10 ⁹ /L) (median, Q1-Q3)	0.98 [0.70 – 1.36]	0.99 [0.74 – 1.41]	0.845 [0.5675 – 1.2675]	0.1469
PCT ² (ng/mL) (median, Q1-Q3)	0.13 [0.07 - 0.41]	0.12 [0.07 - 0.2853]	0.3595 [0.09 – 0.5575]	0.0307
MR-proADM (nmol/L) (median, Q1-Q3)	1.02 [0.71 - 1.61]	0.899 [0.6284 - 1.316]	1.842 [1.3943 – 2.6323]	<0.00001

Table 2. Univariate Cox regression for prediction of 30-day mortality, requirement of critical care, NIV and intubation and ventilation using biomarkers in baseline bloods

Biomarker	Patients (N)	Cases (N)	Wald	D.F.	C-index [95% CI]	HR [95% CI]	p-value		
Prediction of 30-day mortality									
MR-proADM	135	30	20.3	1	0.811 [0.746-0.876]	1.5455 [1.279-1.868]	6.64e-6		
CRP ¹	135	30	4.02	1	0.613 [0.515-0.711]	1.0034 [1.000-1.007]	0.0449		
PCT ²	116	26	11.54	1	0.621 [0.511-0.731]	1.0898 [1.037-1.145]	0.000681		
Neutrophils	135	30	0.73	1	0.549 [0.445-0.653]	0.9555 [0.861-1.061]	0.394		
Lymphocytes	135	30	3.53	1	0.448 [0.338-0.558]	1.0920 [0.996-1.197]	0.0603		
Prediction of requ	iring critical	care admis	sion						
MR-proADM	135	31	3.2	1	0.614 [0.518-0.710]	1.2570 [0.978-1.615]	0.0737		
CRP ¹	135	31	15.83	1	0.716 [0.624-0.808]	1.0055 [1.003-1.008]	0.0000695		
PCT ²	116	31	0.03	1	0.687 [0.595-0.779]	1.0050 [0.951-1.062]	0.86		
Neutrophils	135	31	0.37	1	0.609 [0.511-0.707]	1.0183 [0.960-1.080]	0.544		
Lymphocytes	135	31	2.52	1	0.465 [0.357-0.573]	1.0759 [0.983-1.178]	0.113		
Prediction of requ	iring NIV								
MR-proADM	135	23	11.62	1	0.726 [0.634-0.818]	1.4992 [1.188-1.892]	0.000651		
CRP ¹	135	23	15.53	1	0.725 [0.617-0.833]	1.0061 [1.003-1.009]	0.0000813		
PCT ²	116	22	0.1	1	0.772 [0.682-0.862]	1.0098 [0.952-1.072]	0.747		
Neutrophils	135	23	0.06	1	0.432 [0.324-0.540]	0.9883 [0.901-1.085]	0.804		
Lymphocytes	135	23	4.81	1	0.552 [0.442-0.662]	1.0991 [1.010-1.196]	0.0283		
Prediction of intuk	Prediction of intubation and ventilation								
MR-proADM	135	16	12.37	1	0.748 [0.650-0.846]	1.6015 [1.232-2.082]	0.000435		
CRP ¹	135	16	16.57	1	0.745 [0.614-0.876]	1.0069 [1.004-1.010]	0.0000469		
PCT ²	116	16	0.63	1	0.836 [0.746-0.926]	1.0215 [0.969-1.077]	0.429		
Neutrophils	135	16	0.43	1	0.641 [0.514-0.768]	1.0259 [0.950-1.107]	0.513		
Lymphocytes	135	16	0.09	1	0.468 [0.337-0.599]	0.9415 [0.630-1.408]	0.769		

¹ C-reactive protein

² Procalcitonin

Table 3. Multivariate Cox regression for prediction of 30-day mortality, requirement of critical care, NIV and intubation and ventilation using biomarkers in baseline bloods

Biomarker	Patients (N)	Cases (N)	Wald	D.F.	C-index [95% CI]	HR [95% CI]	p-value		
Prediction of 30-day mortality									
MR-proADM	135	30	23.736	5	0.827 [0.756-0.898]	1.8709 [1.454-2.407]	1.1e-6		
CRP ¹	135	30	12.166	5	0.788 [0.704-0.872]	1.0069 [1.003-1.011]	0.000487		
PCT	116	26	-	-	-	-	-		
Neutrophils	135	30	0.9235	5	0.808 [0.745-0.871]	0.9445 [0.841-1.061]	0.336303		
Lymphocytes	135	30	6.6564	5	0.791 [0.713-0.869]	1.1213 [1.028-1.223]	0.009879		
Prediction of re	quiring critic	al care a	dmission						
MR-proADM	135	31	10.151	5	0.713 [0.621-0.805]	1.5451 [1.182-2.019]	0.00144		
CRP ¹	135	31	22.062	4	0.775 [0.702-0.848]	1.0078 [1.005-1.011]	2.64e-6		
PCT ²	116	31	0.6084	5	0.715 [0.631-0.799]	1.0254 [0.963-1.092]	0.43564		
Neutrophils	135		0.5761	5	0.686 [0.596-0.776]	1.0221 [0.966-1.081]	0.44772		
Lymphocytes	135	31	1.4066	5	0.689 [0.599-0.779]	1.0638 [0.961-1.178]	0.23544		
Prediction of re	quiring NIV			•					
MR-proADM	135	23	30.393	5	0.828 [0.740-0.916]	2.5230 [1.816-3.506]	3.53e-8		
CRP ¹	135	23	18.293	5	0.799 [0.725-0.873]	1.0081 [1.004-1.012]	1.89e-5		
PCT ²	116	22	1.39	5	0.755 [0.659-0.851]	1.0454 [0.971-1.125]	0.2383		
Neutrophils	135	23	0.0266	5	0.72 [0.616-0.824]	0.9923 [0.905-1.089]	0.8706		
Lymphocytes	135	23	-	-	-	-	-		
Prediction of in	tubation and	d ventilat	tion						
MR-proADM	135	16	22.648	5	0.793 [0.687-0.899]	2.2457 [1.609-3.134]	1.94e-6		
CRP ¹	135	16	18.318	5	0.803 [0.713-0.893]	1.0088 [1.005-1.013]	1.87e-5		
PCT ²	116	16	2.241	5	0.715 [0.617-0.813]	1.0558 [0.983-1.134]	0.134		
Neutrophils	135	16	0.4543	5	0.665 [0.563-0.767]	1.0254 [0.953-1.103]	0.500		
Lymphocytes	135	16	0.2663	5	0.67 [0.554-0.786]	0.8260 [0.400-1.707]	0.606		

Figure 1. Univariate Receiver Operating Characteristic Curves for predicting outcomes starting top-left and progressing clockwise towards bottom-left A) 30 Day Mortality B) Critical Care Admission C) NIV Use D) Intubation and Ventilation




Figure 2. Multivariate Receiver Operating Characteristic Curves for predicting outcomes, starting top-left and progressing clockwise A) 30 Day Mortality B) Critical Care Admission and C) NIV Use




Table 4. Univariate area under receiver operating characteristic curve data for predicting various outcomes from baseline bloods

Biomarker	Patients (N)	Cases (N)	D.F.	AUC [95% CI]
30 day mortality			•	
MR-proADM	135	30	1	0.8441 [0.7761-0.9122]
CRP ¹	135	30	1	0.6132 [0.5066-0.7198]
PCT ²	116	26	1	0.6212 [0.4963-0.7460]
Neutrophils	135	30	1	0.5503 [0.4356-0.6650]
Lymphocytes	135	30	1	0.5629 [0.4373-0.6884]
Critical Care Admission	on			
MR-proADM	135	31	1	0.594 [0.4873-0.7007]
CRP ¹	135	31	1	0.7238 [0.6213-0.8263]
PCT ²	116	31	1	0.6856 [0.5771-0.7941]
Neutrophils	135	31	1	0.6158 [0.5104-0.7213]
Lymphocytes	135	31	1	0.5296 [0.4147-0.6446]
NIV				
MR-proADM	135	23	1	0.7189 [0.617-0.8209]
CRP ¹	135	23	1	0.722 [0.6068-0.8373]
PCT ²	116	22	1	0.7706 [0.6734-0.8677]
Neutrophils	135	23	1	0.5615 [0.4505-0.6726]
Lymphocytes	135	23	1	0.5646 [0.4476-0.6817]
Intubation and Venti	lation	•		_
MR-proADM	135	16	1	0.75 [0.6434-0.8566]
CRP ¹	135	16	1	0.7545 [0.6059-0.903]
PCT ²	116	16	1	0.8497 [0.7565-0.9429]
Neutrophils	135	16	1	0.6476 [0.5104-0.7848]
Lymphocytes	135	16	1	0.468 [0.324-0.612]

Table 5. Multivariate area under receiver operating characteristic data for predicting various outcomes from baseline bloods

Biomarker	Patients (N)	Cases (N)	D.F.	AUC [95% CI]	Bootstrap
30 day mortality					•
MR-proADM	135	30	5	0.874 [0.8085-0.9395]	0.01727
CRP ¹	135	30	5	0.8441 [0.769-0.9192]	0.1464
PCT ²	116	26	5	0.8406 [0.7619-0.9193]	0.06908
Neutrophils	135	30	5	0.8394 [0.7667-0.9121]	0.1417
Lymphocytes	135	30	5	0.8448 [0.7716-0.918]	0.1056
Critical Care Admis	sion				
MR-proADM	135	31	5	0.7466 [0.6553-0.8379]	0.1457
CRP ¹	135	31	5	0.8026 [0.7256-0.8796]	0.012
PCT ²	116	31	5	0.7632 [0.6747-0.8517]	0.1465
Neutrophils	135	31	5	0.7252 [0.6359-0.8145]	0.2458
Lymphocytes	135	31	5	0.7317 [0.6413-0.8221]	0.2132
NIV					
MR-proADM	135	23	5	0.8544 [0.7727-0.9362]	0.000375
CRP ¹	135	23	5	0.8139 [0.7374-0.8904]	0.001052
PCT ²	116	22	5	0.7872 [0.6884-0.8861]	0.03331
Neutrophils	135	23	5	0.7418 [0.6341-0.8496]	0.07907
Lymphocytes	135	23	5	0.7519 [0.6461-0.8578]	0.05353
Intubation and Ver	ntilation				
MR-proADM	135	16	5	0.812 [0.7071-0.9169]	0.005858
${\sf CRP}^1$	135	16	5	0.8183 [0.7176-0.9189]	0.002934
PCT ²	116	16	5	0.7256 [0.6193-0.8319]	0.1324
Neutrophils	135	16	5	0.6817 [0.576-0.7874]	0.2557
Lymphocytes	135	16	5	0.6838 [0.5664-0.8012]	0.2675

Discussion

323

324

325 326 327

328

329

330

331

332

333

334335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352353

354

355356

357 358 Our study demonstrates that use of biomarkers, both established and novel, has significant potential to support clinical decisions and aid in identification of COVID-19 patients at both high and low risk for disease progression. Of the biomarkers evaluated, elevated MR-proADM and CRP concentrations showed the greatest potential for clinical application for utilisation to aid prediction of 30-day mortality, critical care admission requirement and need for both invasive and non-invasive ventilation.

Of these, on multivariate regression analysis MR-proADM concentration showed the strongest association with an increased 30-day mortality, requirement for non-invasive and invasive ventilation, with CRP showing the strongest association with critical care admission. Our data are also suggestive of an association between elevated MR-proADM and CRP concentration with a progression to being intubated and ventilated, though more cases are required to verify this by controlling for covariates. This is consistent with previous studies that have shown increased MRproADM levels to be predictive of intensive care requirement.(17) Gonzalez del Castillo et al. identified MR-proADM to have the strongest association for ICU admission and mortality compared to other blood biomarkers; with concentrations of >1.77nmol/L having significantly higher rates of ICU stay (8.1% vs 1.6%; p<0.001) and disease progression (29.7% vs 4.9%; p<0.001) compared to low MR-proADM concentrations.(18) Application of these and our own findings, applying previously derived thresholds of 0.88 and 1.54nmol/L may support clinicians with decisions regarding earlier transfer of selected patients to wards with staff with experience in non-invasive ventilation, earlier transfer to critical care and dependent on emerging trial data, potentially those who are at low risk of deterioration suitable for ambulant monitoring. Similarly, subject to future studies, biomarker concentrations may have significant value in signalling patients suitable for earlier commencement of targeted therapies, including antiviral treatments (e.g. remdesivir) or immunomodulation with high dose steroids or interleukin-6 inhibitors (e.g. tocilizumab & sarilumab); in the NHS the latter are subject in the UK to specific inclusion criteria which includes physiological derangement and requirement for respiratory support. (19, 20)

Previous studies examining the clinical utility of MR-proADM have focussed on predicting adverse events, primarily in patients with a diagnosis of community-acquired pneumonia and elevated MR-proADM levels, (4) reflecting the development of organ dysfunction. However, these patients

typically have had low rates of severe viral infection.(11, 21) We have shown commensurate results in individuals diagnosed with SARS-CoV-2 infections. This may be explained by the development of endothelial dysfunction during SARS-CoV-2 infection, for which endoreticular stress and the activation of the unfolded protein response is a significant inducer. Endothelial dysfunction is associated with complications of Covid-19 including ARDS, thromboembolism and vascular disease, with Adrenomedullin known to be a regulator of vascular tone and the integrity and stability of the endothelial barrier.

The early recognition of potential for deterioration in patients infected with SARS-CoV-2 is invariably challenging given the varied clinical course of the disease; particularly with the currently unpredictable potential for deterioration during the second and third weeks of disease. As such, a reliable indicator for early identification of patients at risk of deterioration or a more severe illness trajectory could be of great value, in allowing for earlier targeted intervention or escalation of treatment.

The study has several limitations. Primarily, a higher event per variable ratio is desirable, fortunately however stratification was only needed for one covariate. Greater power could be achieved through higher participant numbers or through examining serial results over time. A multi-centre study with more patients could also allow for prediction of progression from NIV to intubation. It is a retrospective study; it remains to be seen whether application of such biomarkers into clinical diagnostic and management pathways will deliver the potential expected benefits. Clinician confidence in use of such biomarkers to support decisions has to be developed and evidenced in clinical practice.

MR-proADM and CRP may have other clinical utility worth exploring, such as whether measurement of these has use in facilitating earlier discharges (11) in individuals with low concentrations or whether a delta change in concentrations could be used to guide decisions on weaning ventilatory support and also the de-escalation or stopping of antibiotics to mitigate against potential future antimicrobial resistance.

Conclusions

Biomarker measurement, in particular MR-proADM, in patients infected with SARS-CoV-2 upon presentation to secondary care shows significant promise in allowing early identification of those at increased risk of disease progression and mortality, possibly providing a tool to support clinical decisions regarding therapeutic interventions and level of care setting. Additionally, adopting use of biomarkers such as MR-proADM in the acute setting carries potential in allowing identification of those at low-risk for severe disease, facilitating discharge decisions. Further prospective, multicentre studies are needed to investigate possible exciting clinical applications of this and other biomarkers.

- 404 **Author Contributions** NAM, MY, KG and NC contributed to the study conception and design.
- 405 Material preparation was performed by TL. Data collection was performed by RW, MM, BB, GV and
- JL. Analysis was performed by NAM and PP. The first draft of the manuscript was written by NAM.
- RW, SPK, CT, VGA, KS, KG and NC commented on previous versions of the manuscript. All authors read and approved the final manuscript.
- 410 Ethical approval Local Hampshire Hospitals NHS Foundation Trust R&D approval was obtained. HRA
- 411 Approval was sought who deemed an ethical review was not necessary. HRA Approval was
- 412 subsequently granted for this project (IRAS project ID: 299130). Anonymised confidential patient
- information was used under the COVID-19 COPI notice issued by the UK Department of Health and Social Care
- 415

416

417

418

419

420

- **Conflicts of Interest** Thermofisher (UK) provided reagent for measurement of MR-proADM free of charge. PP received payment from Thermo Fisher (Germany), however this did not have any role in the collection, management, analysis, or interpretation of the data, in the preparation, review, or approval of the manuscript, or in the decision to submit the manuscript for publication. There are no non-financial interests.
- 426 1. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al.
- 427 Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417-8.
- 2. Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, et al. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020;5(11).
- 430 3. Gille J, Ostermann H, Dragu A, Sablotzki A. MR-proADM: A New Biomarker for Early Diagnosis of Sepsis in Burned Patients. J Burn Care Res. 2017;38(5):290-8.
- 432 4. Elke G, Bloos F, Wilson DC, Brunkhorst FM, Briegel J, Reinhart K, et al. The use of mid-433 regional proadrenomedullin to identify disease severity and treatment response to sepsis - a 434 secondary analysis of a large randomised controlled trial. Crit Care. 2018;22(1):79.
- 5. Elke G, Bloos F, Wilson DC, Meybohm P, Group SCCT. Identification of developing multiple organ failure in sepsis patients with low or moderate SOFA scores. Crit Care. 2018;22(1):147.
- 437 6. Legramante JM, Mastropasqua M, Susi B, Porzio O, Mazza M, Miranda Agrippino G, et al.
- 438 Prognostic performance of MR-pro-adrenomedullin in patients with community acquired pneumonia 439 in the Emergency Department compared to clinical severity scores PSI and CURB. PLoS One.
- 440 2017;12(11):e0187702.
- 7. Pereira JM, Azevedo A, Basílio C, Sousa-Dias C, Mergulhão P, Paiva JA. Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia? Rev Port Pneumol (2006). 2016;22(6):308-14.
- 444 8. Stalenhoef JE, van Nieuwkoop C, Wilson DC, van der Starre WE, Delfos NM, Leyten EMS, et 445 al. Biomarker guided triage can reduce hospitalization rate in community acquired febrile urinary 446 tract infection. J Infect. 2018;77(1):18-24.
- 447 9. van der Starre WE, Zunder SM, Vollaard AM, van Nieuwkoop C, Stalenhoef JE, Delfos NM, et
- 448 al. Prognostic value of pro-adrenomedullin, procalcitonin and C-reactive protein in predicting
- outcome of febrile urinary tract infection. Clin Microbiol Infect. 2014;20(10):1048-54.
- 450 10. von Haehling S, Filippatos GS, Papassotiriou J, Cicoira M, Jankowska EA, Doehner W, et al.
- 451 Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart
- 452 failure. Eur J Heart Fail. 2010;12(5):484-91.

- 453 11. Saeed K, Wilson DC, Bloos F, Schuetz P, van der Does Y, Melander O, et al. The early
- 454 identification of disease progression in patients with suspected infection presenting to the
- emergency department: a multi-centre derivation and validation study. Crit Care. 2019;23(1):40.
- 456 12. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox
- 457 regression. Am J Epidemiol. 2007;165(6):710-8.
- 458 13. Riley RD, Snell KI, Ensor J, Burke DL, Harrell FE, Moons KG, et al. Minimum sample size for
- developing a multivariable prediction model: PART II binary and time-to-event outcomes. Stat Med.
- 460 2019;38(7):1276-96.
- 461 14. Group RC. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a
- randomised, controlled, open-label, platform trial. Lancet. 2021;397(10274):605-12.
- 463 15. Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, et al. Effect of
- 464 Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020;383(21):2030-40.
- 465 16. Group RC. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a
- randomised, controlled, open-label, platform trial. Lancet. 2020.
- 467 17. Baldirà J, Ruiz-Rodríguez JC, Wilson DC, Ruiz-Sanmartin A, Cortes A, Chiscano L, et al.
- 468 Biomarkers and clinical scores to aid the identification of disease severity and intensive care
- requirement following activation of an in-hospital sepsis code. Ann Intensive Care. 2020;10(1):7.
- 470 18. Gonzalez Del Castillo J, Wilson DC, Clemente-Callejo C, Román F, Bardés-Robles I, Jiménez I,
- et al. Biomarkers and clinical scores to identify patient populations at risk of delayed antibiotic
- administration or intensive care admission. Crit Care. 2019;23(1):335.
- 473 19. Improvement NEaN. Interim Clinical Commissioning Policy: Tocilizumab for critically ill
- 474 patients with COVID-19 pneumonia (adults)
- 475 https://www.england.nhs.uk/coronavirus/publication/interim-clinical-commissioning-policy-
- 476 <u>tocilizumab-for-hospitalised-patients-patients-with-covid-19-pneumonia-adults/</u>: NHS England and
- 477 NHS Improvement; 2021 [
- 478 20. Improvement NEaN. Interim Clinical Commissioning Policy: Sarilumab for critically ill patients
- with COVID-19 pneumonia (adults) https://www.england.nhs.uk/coronavirus/publication/interim-
- 480 <u>clinical-commissioning-policy-sarilumab-for-critically-ill-patients-with-covid-19-pneumonia-adults/</u>:
- 481 NHS England and NHS Improvement; 2021 [
- 482 21. Xie Z, Chen WS, Yin Y, Chan EC, Terai K, Long LM, et al. Adrenomedullin surges are linked to
- 483 acute episodes of the systemic capillary leak syndrome (Clarkson disease). J Leukoc Biol.
- 484 2018;103(4):749-59.